A Phase 1/2 interventional study of Acupuncture in Migraine, sponsored by University of West London. Enrolling by invitation at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-04.
Sponsored by University of West London · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Migraine Disorders with a site in United Kingdom — 11 open to participants now, 18 under way, 13 of them phase 3. Migraine Disorders · United Kingdom.
Among the 80 studies in Migraine Disorders with a site in United Kingdom, this one is the 57th largest by planned enrollment of the 70 interventional ones that give a count, is one of 4 that started in 2024, is the only one in phase 1/2, reaches primary completion later than 2 of the 17 other live ones, and was the 74th registered.
1,659 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →11 of the 80 studies in Migraine Disorders with a site in United Kingdom are open now. Recruiting first, the newest first:
Pfizer · Sites in United Kingdom, United States, China and 1 more country
Ages 18+
Pfizer · Sites in United Kingdom, United States, Argentina and 12 more countries
Ages 18–45 · Women only
AbbVie · Sites in United Kingdom, United States, Canada and 8 more countries
Ages 12–17
King's College London · Sites in United Kingdom
Ages 18+
H. Lundbeck A/S · Sites in United Kingdom, United States, Argentina and 8 more countries
Ages 6–17
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 11 · Phase 3 34 · Phase 4 7
First in 2003; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 80 across 1,271 interventional studies indexed under Migraine Disorders.
Median enrollment 466 across the 70 interventional studies, 593 across the 10 observational. Of the 58 that completed or were terminated, 33 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
65 of 80 have an industry lead sponsor. The 10 most frequent:
University of West London is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
University of West London has 1 study filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
6 of the studies in Migraine Disorders with a site in United Kingdom that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641466Phase 3PfizerA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | 2026-11-29 |
| NCT07018700Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine | 2027-03 |
| NCT07018713Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine | 2027-03 |
| NCT04965675Phase 3H. Lundbeck A/SA Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | 2027-03-26 |
| NCT05897320Phase 3H. Lundbeck A/SA Study of Eptinezumab in Pediatric Participants With Episodic Migraine | 2027-07-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 80 studies in Migraine Disorders with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients who have had a course of acupuncture at the Royal London Hospital for Integrated Medicine to manage their migraines, and found it effective, will be taught to do self-acupuncture. This is a feasibility study so the main aim is to test the trial design but the researchers will also explore self-acupuncture's effectiveness, acceptability and safety.
Aim: The proposed study will evaluate the feasibility of teaching SA to patients with migraines in the United Kingdom National Health Service setting.
Methodology: The study will employ a pragmatic, mixed-methods, randomised, parallel-group, exploratory design. The study will compare SA plus standard care versus standard care alone. Participants will complete outcome measures at various time points and be invited to take part in a qualitative telephone interview to explore their views on the design of the study and acceptability of the intervention. The researcher will take field notes of the observation of the SA teaching session to explore the acceptability of the SA teaching method. Data will be analysed to test the hypothesis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will be taught to do self-acupuncture to manage their migraines. They can also do all the other things they normally do to manage their migraines apart from having acupuncture elsewhere.
Device: Acupuncture
Participants can do all the other things they normally do to manage their migraines apart from having acupuncture elsewhere.
self-acupuncture
Headache Impact Test (HIT6)
HIT-6 assesses the burden of headaches (including migraine) by assessing the impact of headaches on peoples' daily living, work and social situations. Patients rate six areas of potential impact on a 5-part scale from 'never' to 'always'.
Time frame: From enrolment to end of intervention at 24 weeks
Migraine Disability Assessment (MIDAS)
MIDAS assesses the impact headaches or migraines have on peoples' daily living. Patients record the number of days in the last three months that their migraine has impacted their work, household work and social activities (there are five items in the measure).
Time frame: From enrolment to end of intervention at 24 weeks
Migraine-Specific Quality of Life Questionnaire (MSQ v2.1)
MSQ v2.1 assesses the impact of migraine on peoples' quality of life. Patients rate how often in the last four weeks their migraine has impacted various areas of daily living. The questionnaire consists of 14 questions which relate to three areas: daily activities the patient was restricted from doing, daily activities the patient was prevented from doing and impact on emotional wellbeing. Patients can rate the impact of each item on a 6-part scale from 'none of the time' to 'all of the time'.
Time frame: From enrolment to end of intervention at 24 weeks
Pain Catastrophising Scale (PCS)
The PCS measures the impact of pain on peoples' daily living. The questionnaire consists of 13 items. Patients rate the impact pain has on these items on a 5-part scale from 'not at all' to 'all of the time'.
Time frame: From enrolment to end of intervention at 24 weeks
Migraine diary
Participants will be asked to keep a diary of their migraines. They will be asked to record the frequency, duration and severity of their migraines, other symptoms they experienced (such as dizziness or nausea), any migraine or pain medication they took and any other comments.
Time frame: From enrolment to end of intervention at 24 weeks
Plan to share: Undecided — I'm not sure what it involves
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Sep 2025, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of West London